Benjamin Ticho, MD
Ophthalmology · Chicago Ridge, ILNPI 1992782494
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,904 of the $8,335 with a category attached, or 82.8%. 30 manufacturers reported payments, led by Amgen at 26.0% of the total. Reporting peaked in 2024 at $2,383 and has fallen 51.6% since, to $1,154 in 2025.
Across 211 payments — averaging $39.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AbbVie$1K
- Mallinckrodt Hospital Products Inc.$764
- Sight Sciences, Inc.$716
- Alcon$702
- Sun Pharmaceutical Industries Inc.$462
- plus $3K from 24 others
Across 10 payments — averaging $2975.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$22K
- Novartis$7K
What the payments were for
- Consulting fees$1,20014%
- Food & beverage$6,90483%
- Education$1982%
- Gifts$320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 24 | $2,170 |
| AbbVie(2 entities) | 35 | $1,015 |
| Mallinckrodt Hospital Products Inc. | 17 | $764 |
| Sight Sciences, Inc. | 18 | $716 |
| Alcon | 22 | $702 |
| Sun Pharmaceutical Industries Inc. | 9 | $462 |
| NEW World Medical,inc. | 16 | $423 |
| Merz North America, Inc. | 3 | $328 |
| Bausch & Lomb Americas Inc. | 9 | $256 |
| Biotissue Holdings Inc. | 2 | $172 |
| Novartis | 11 | $170 |
| ABB Con-cise Optical Group LLC | 3 | $155 |
| Eyevance Pharmaceuticals LLC | 9 | $148 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $138 |
| Tarsus Pharmaceuticals, Inc. | 4 | $117 |
| Glaukos Corporation | 2 | $99 |
| Dompe US, Inc. | 4 | $89 |
| Harrow Eye, LLC | 3 | $74 |
| Iridex Corporation | 1 | $52 |
| Beaver-visitec International, Inc. | 2 | $48 |
| LKC Technologies, Inc. | 1 | $37 |
| Travere Therapeutics, Inc. | 3 | $31 |
| Astellas Pharma US Inc | 2 | $29 |
| Rayner Intraocular Lenses Limited | 1 | $27 |
| Rxsight Inc | 1 | $23 |
| Merz Pharmaceuticals, LLC | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Oasis Medical, Inc. | 1 | $19 |
| Ocular Therapeutix, Inc. | 1 | $15 |
| Boston Scientific | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$1,705
- OMNI(R) SURGICAL SYSTEM (US)$272
- SION SURGICAL INSTRUMENT$272
- CEQUA$240
- DURYSTA$228
- INFUSE MULTIFOCAL$125
- Clareon$122
- AcrySof IQ VIVITY$117
- ACTHAR$115
- TEARCARE SYSTEM$107
- Kahook Dual Blade$106
- Streamline Surgical System$106
- Ahmed Glaucoma Valve$106
- VUITY$101
How this compares
$8,335 in reported general payments places this provider in the 85th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 30 | $25,657 |
| XiidraLifitegrast | 20 | $15,545 |
| LumiganBimatoprost | 29 | $13,236 |
| Cyclosporine | 31 | $11,556 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $7,685 |
| AzoptBrinzolamide | 17 | $6,076 |
| Brimonidine Tartrate | 63 | $5,085 |
| Travoprost | 22 | $4,731 |
| Latanoprost | 404 | $3,939 |
| Alphagan PBrimonidine Tartrate | 13 | $3,129 |
| Prednisolone Acetate | 70 | $2,998 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 110 | $2,244 |
| Timolol Maleate | 160 | $1,733 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 90 | $971 |
| Ofloxacin | 68 | $964 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,015 | $49,70785 claims |
| Bausch & Lomb Americas Inc.Xiidra | $256 | $15,54520 claims |
| AlconAzopt | $702 | $6,07617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Chicago Ridge
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.7M
- Kathleen MornoNorth Riverside$1.2M
- Veeral ShethOak Forest$716K
- James KatzDes Plaines$642K
- Mitchell JacksonLake Villa$584K
- David LubeckHomewood$575K
- Parag MajmudarHighland Park$451K
- Daniel OwensLombard$343K
- Yannek LeidermanChicago$312K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.